Long-Term Follow-Up Results of Antiseizure Medication Withdrawal in Grade 2 and 3 Glioma Patients
This study provides Class III evidence that withdrawal of ASM does not significantly increase the risk of recurrent seizures in patients with glioma with stable disease and no seizures for >1 year. Confidence intervals do not exclude a clinically important increased risk of seizures.
Authors
- Johan A F Koekkoek (ORCID: https://orcid.org/0000-0002-3648-9616)
- Marta Fiocco (ORCID: https://orcid.org/0000-0001-5588-0277)
- Martin J. van den Bent (ORCID: https://orcid.org/0000-0001-5710-5127)
- Tjeerd J. Postma
- Jacoline E. C. Bromberg (ORCID: https://orcid.org/0000-0002-3830-7142)
- Linda Dirven (ORCID: https://orcid.org/0000-0001-9157-9895)
- Mathilde C.M. Kouwenhoven (ORCID: https://orcid.org/0000-0001-5252-4365)
- Pim B. van der Meer (ORCID: https://orcid.org/0000-0003-3700-8906)
- Martin Taphoorn (ORCID: https://orcid.org/0000-0001-9949-4722)
- Melissa Kerkhof (ORCID: https://orcid.org/0000-0002-1875-9387)
- Maaike J. Vos (ORCID: https://orcid.org/0000-0002-7759-8050)
Institutions
- Leiden University (NL)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Medisch Centrum Haaglanden (NL)
- Princess Máxima Center (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1212/wnl.0000000000213590
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.25